Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Alere has received FDA approval to market its Alere Determine HIV-1/2 Ag/Ab Combo in the United States. The Alere Determine HIV-1/2 Ag/Ab Combo is a rapid point-of-care test that detects both HIV-1/2 antibodies and the HIV-1 p24 antigen, which can appear days after infection and prior to HIV-1/2 antibodies.
BD Diagnostics and Diagenode announced the European-only launch of the Diagenode Bordetella pertussis/parapertussis real-time PCR kit for use on the BD Max system. The kit has been CE-marked and validated to run on the BD Max system using the BD Max ExK DNA-1 extraction kit, an open-system reagent. BD Diagnostics, 800-675-0938 Diagenode, 862-209-4680
PolyScience’s performance programmable circulating baths make it simple to create and run multi-step ramp and soak temperature programs as well as frequently used single temperature testing protocols. The baths have an icon-driven touchscreen display that makes it easy to select and set operational parameters. A built-in electronic keypad speeds and simplifies the entry of text and numerical values. Available in refrigerating/heating and heat-only models, PolyScience performance programmable circulating baths control bath temperatures from −40°C to 200°C with ±0.005°C stability and
Qiagen announced a partnership with Exosome Diagnostics to develop and commercialize high-performance biofluid sample preparation kits for the processing of nucleic acids from exosomes. Combining Exosome Diagnostics’ platform technology approach with select Qiagen consumables and automation platforms has the potential to allow researchers, drug developers, and medical professionals to take repeated, real-time genetic “snapshots” of disease from patients’ blood, urine, or cerebrospinal fluid without the need for tissue biopsy. Qiagen’s exosome technology-driven kits will offer the ability to work with
Immunetics has received FDA clearance for its BacTx rapid test for bacteria in apheresis platelets. The BacTx system is a colorimetric assay that can detect aerobic, anaerobic, gram-negative, and gram-positive bacteria in a single test. The BacTx assay uses a patented, specific, universal bacterial detection reagent that has been shown to detect wild and cultured bacterial strains. BacTx is intended for use as a point-of-issue test performed at the transfusion site on the day of issue. The BacTx assay can
ELGA Process Water introduces the Medica Pro electrodeionization (EDI) water purification system. The system consistently produces high-purity water at economical running costs for immunochemistry and general chemistry automated clinical analyzers. ELGA’s Pulse technology combined with extended intervals between sanitization reduces maintenance time.
Diagnostic BioSystems’ anti-PIN5 cocktail helps distinguish prostate cancer from benign conditions that mimick cancer. The cocktail works through the combined detection of p504S, p40, and high molecular-weight cytokeratin markers. The markers are particularly relevant in helping to diagnose prostatic intraepithelial neoplasia. The markers also offer utility in difficult cases where tissue may be limited.
Sysmex America has renewed its agreement to distribute Medica’s EasyCell assistant for digital cell image analysis in hematology laboratories. EasyCell uses optical pattern recognition software to automatically locate white cells on a blood smear. It digitally stores, preclassifies, and presents images for review, grouped by cell type, on an LCD display.
Randox Laboratories has received FDA approval for its Acusera immunoassay specialty 1 control for use in U.S. laboratories. The multi-analyte, lyophilized control contains I-25-(OH)2-vitamin D, 25-OH-vitamin D, C peptide, insulin, insulin-like growth factor-1, procalcitonin, parathyroid hormone, anti-thyroglobulin, and anti-thyroperoxidase.
SciGene’s CytoZyme stabilized pepsin is an advanced formulation of pepsin for pretreating tissue samples in nucleic acid probe-based cytogenetic assays, including FISH.
